Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Tongue Neoplasms 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gliosarcoma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 29Gemcitabine 16Cyclophosphamide 14Nivolumab 12Carboplatin 12Capecitabine 11Trastuzumab 9Paclitaxel 9Magnetic Resonance Spectroscopy 8Irinotecan 8Bevacizumab 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8olaparib 7fludarabine 7Docetaxel 7spartalizumab 6aldesleukin 6Drug Therapy 6Cisplatin 6durvalumab 5atezolizumab 5Standard of Care 5Specimen Handling 5Oxaliplatin 5Biopsy 5sargramostim 4palbociclib 4niraparib 4enzalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × FPP(RGD)2 × Breast × Clear all
NCT01806675 2019-10-03

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Stanford University

Phase 1/2 Completed
25 enrolled 14 charts
BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡